EA201490451A1 - Новые соединения - ингибиторы ферментов - Google Patents
Новые соединения - ингибиторы ферментовInfo
- Publication number
- EA201490451A1 EA201490451A1 EA201490451A EA201490451A EA201490451A1 EA 201490451 A1 EA201490451 A1 EA 201490451A1 EA 201490451 A EA201490451 A EA 201490451A EA 201490451 A EA201490451 A EA 201490451A EA 201490451 A1 EA201490451 A1 EA 201490451A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- pyridin
- chlorophenyl
- pyrazolo
- piperidin
- pyrrolo
- Prior art date
Links
- 239000002532 enzyme inhibitor Substances 0.000 title 1
- 125000000022 2-aminoethyl group Chemical group [H]C([*])([H])C([H])([H])N([H])[H] 0.000 abstract 4
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 abstract 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 2
- WGYKZJWCGVVSQN-UHFFFAOYSA-N propylamine Chemical group CCCN WGYKZJWCGVVSQN-UHFFFAOYSA-N 0.000 abstract 2
- VKIWDHXNHBXEIH-UHFFFAOYSA-N 1-[1-(4-chlorophenyl)pyrazolo[3,4-c]pyridin-3-yl]piperidine-4-carboxylic acid Chemical compound C1CC(C(=O)O)CCN1C(C1=CC=NC=C11)=NN1C1=CC=C(Cl)C=C1 VKIWDHXNHBXEIH-UHFFFAOYSA-N 0.000 abstract 1
- BKCPIIKZPOOFMV-UHFFFAOYSA-N 1-[4-[1-(4-chlorophenyl)pyrrolo[2,3-c]pyridin-3-yl]piperidin-1-yl]-4-(dimethylamino)butan-1-one Chemical compound C1CN(C(=O)CCCN(C)C)CCC1C(C1=CC=NC=C11)=CN1C1=CC=C(Cl)C=C1 BKCPIIKZPOOFMV-UHFFFAOYSA-N 0.000 abstract 1
- XLMWNMLTMRLNHE-UHFFFAOYSA-N 2-[4-[1-(4-chlorophenyl)pyrazolo[3,4-c]pyridin-3-yl]morpholin-3-yl]ethanol Chemical compound OCCC1COCCN1C(C1=CC=NC=C11)=NN1C1=CC=C(Cl)C=C1 XLMWNMLTMRLNHE-UHFFFAOYSA-N 0.000 abstract 1
- ZXMLQCJUWUMPIR-UHFFFAOYSA-N 2-[4-[1-(4-chlorophenyl)pyrrolo[2,3-c]pyridin-3-yl]piperidin-1-yl]ethanamine Chemical compound C1CN(CCN)CCC1C(C1=CC=NC=C11)=CN1C1=CC=C(Cl)C=C1 ZXMLQCJUWUMPIR-UHFFFAOYSA-N 0.000 abstract 1
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 abstract 1
- YZXLJBAURSYRBM-UHFFFAOYSA-N 5-amino-1-[4-[1-(4-chlorophenyl)pyrrolo[2,3-c]pyridin-3-yl]piperidin-1-yl]pentan-1-one Chemical compound C1CN(C(=O)CCCCN)CCC1C(C1=CC=NC=C11)=CN1C1=CC=C(Cl)C=C1 YZXLJBAURSYRBM-UHFFFAOYSA-N 0.000 abstract 1
- AHSBRNLPKIICIU-CQSZACIVSA-N [(3r)-4-[1-(4-chlorophenyl)pyrazolo[3,4-c]pyridin-3-yl]morpholin-3-yl]methanol Chemical compound OC[C@@H]1COCCN1C(C1=CC=NC=C11)=NN1C1=CC=C(Cl)C=C1 AHSBRNLPKIICIU-CQSZACIVSA-N 0.000 abstract 1
- UQPLRGBMLZFBEM-UHFFFAOYSA-N [1-[1-(4-chlorophenyl)pyrazolo[3,4-c]pyridin-3-yl]piperidin-4-yl]-morpholin-4-ylmethanone Chemical compound C1=CC(Cl)=CC=C1N1C2=CN=CC=C2C(N2CCC(CC2)C(=O)N2CCOCC2)=N1 UQPLRGBMLZFBEM-UHFFFAOYSA-N 0.000 abstract 1
- ZPDQAZMDJNHKIP-UHFFFAOYSA-N [1-[1-(4-chlorophenyl)pyrazolo[3,4-c]pyridin-3-yl]piperidin-4-yl]-piperazin-1-ylmethanone Chemical compound C1=CC(Cl)=CC=C1N1C2=CN=CC=C2C(N2CCC(CC2)C(=O)N2CCNCC2)=N1 ZPDQAZMDJNHKIP-UHFFFAOYSA-N 0.000 abstract 1
- HYQSSECHZGDUAQ-UHFFFAOYSA-N [4-[1-(4-chlorophenyl)pyrrolo[2,3-c]pyridin-3-yl]piperidin-1-yl]-(1,4-diazepan-1-yl)methanone Chemical compound C1=CC(Cl)=CC=C1N1C2=CN=CC=C2C(C2CCN(CC2)C(=O)N2CCNCCC2)=C1 HYQSSECHZGDUAQ-UHFFFAOYSA-N 0.000 abstract 1
- HUUGOXRVWATWEV-UHFFFAOYSA-N [4-[1-(4-chlorophenyl)pyrrolo[2,3-c]pyridin-3-yl]piperidin-1-yl]-morpholin-4-ylmethanone Chemical compound C1=CC(Cl)=CC=C1N1C2=CN=CC=C2C(C2CCN(CC2)C(=O)N2CCOCC2)=C1 HUUGOXRVWATWEV-UHFFFAOYSA-N 0.000 abstract 1
- NMUZEXQMQNXYNZ-UHFFFAOYSA-N [4-[1-(4-chlorophenyl)pyrrolo[2,3-c]pyridin-3-yl]piperidin-1-yl]-piperazin-1-ylmethanone Chemical compound C1=CC(Cl)=CC=C1N1C2=CN=CC=C2C(C2CCN(CC2)C(=O)N2CCNCC2)=C1 NMUZEXQMQNXYNZ-UHFFFAOYSA-N 0.000 abstract 1
- CYIDIYZCFGLYSZ-UHFFFAOYSA-N [4-[1-(4-methylphenyl)pyrazolo[3,4-c]pyridin-3-yl]morpholin-2-yl]methanol Chemical compound C1=CC(C)=CC=C1N1C2=CN=CC=C2C(N2CC(CO)OCC2)=N1 CYIDIYZCFGLYSZ-UHFFFAOYSA-N 0.000 abstract 1
- NIYSVSJNDYBCLQ-UHFFFAOYSA-N [4-[1-(4-methylphenyl)pyrazolo[3,4-c]pyridin-3-yl]morpholin-3-yl]methanol Chemical compound C1=CC(C)=CC=C1N1C2=CN=CC=C2C(N2C(COCC2)CO)=N1 NIYSVSJNDYBCLQ-UHFFFAOYSA-N 0.000 abstract 1
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Cardiology (AREA)
- Neurology (AREA)
- Pulmonology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Transplantation (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Oncology (AREA)
- Emergency Medicine (AREA)
- Communicable Diseases (AREA)
- Psychiatry (AREA)
- Vascular Medicine (AREA)
- Obesity (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Gastroenterology & Hepatology (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/EP2011/065967 WO2013037411A1 (en) | 2011-09-14 | 2011-09-14 | New enzyme inhibitor compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EA201490451A1 true EA201490451A1 (ru) | 2014-12-30 |
Family
ID=44677871
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA201490451A EA201490451A1 (ru) | 2011-09-14 | 2011-09-14 | Новые соединения - ингибиторы ферментов |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US9150574B2 (https=) |
| EP (1) | EP2755974A1 (https=) |
| JP (1) | JP5796130B2 (https=) |
| CN (1) | CN103889983B (https=) |
| AU (1) | AU2011376717A1 (https=) |
| BR (1) | BR112014005793A2 (https=) |
| CA (1) | CA2847193A1 (https=) |
| EA (1) | EA201490451A1 (https=) |
| IL (1) | IL231353A0 (https=) |
| IN (1) | IN2014DN01883A (https=) |
| SG (1) | SG11201400277VA (https=) |
| WO (1) | WO2013037411A1 (https=) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201304527D0 (en) | 2013-03-13 | 2013-04-24 | Proximagen Ltd | New compounds |
| GB201304526D0 (en) | 2013-03-13 | 2013-04-24 | Proximagen Ltd | New compounds |
| US20160113893A1 (en) | 2013-06-12 | 2016-04-28 | Proximagen Limited | New therapeutic uses of enzyme inhibitors |
| GB201416444D0 (en) | 2014-09-17 | 2014-10-29 | Proximagen Ltd | New compounds |
| GB201416446D0 (en) | 2014-09-17 | 2014-10-29 | Proximagen Ltd | New enzyme inhibitor compounds |
| GB201507031D0 (en) * | 2015-04-24 | 2015-06-10 | Proximagen Ltd | New pharmaceutical salt forms |
| WO2017098236A1 (en) | 2015-12-07 | 2017-06-15 | Proximagen Limited | Vap-1 inhibitors for treating pain |
| MX2019008171A (es) * | 2017-01-09 | 2020-02-05 | Ardelyx Inc | Inhibidores del antiporte mediado por nhe. |
| EP3843846A4 (en) * | 2018-08-27 | 2022-09-07 | Spinogenix, Inc. | FASCIN-BINDING COMPOUNDS FOR SPINOGENESIS |
| EP3976610A1 (en) | 2019-05-29 | 2022-04-06 | Syngenta Crop Protection AG | Microbiocidal derivatives |
| TW202525813A (zh) | 2019-12-19 | 2025-07-01 | 比利時商健生藥品公司 | 經取代之直鏈螺環接衍生物 |
| WO2021209473A1 (en) * | 2020-04-16 | 2021-10-21 | F. Hoffmann-La Roche Ag | Biphenyl derivatives |
| IL308862A (en) | 2021-06-01 | 2024-01-01 | Janssen Pharmaceutica Nv | Altered phenyl-1H-pyrrolo[3,2-c]pyridine histories |
| US20250197392A1 (en) * | 2022-04-08 | 2025-06-19 | Janssen Pharmaceutica Nv | Crystalline forms of an inhibitor of the menin/mll interaction |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6143749A (en) | 1995-06-07 | 2000-11-07 | Abbott Laboratories | Heterocyclic substituted cyclopentane compounds |
| DE19649460A1 (de) | 1996-11-26 | 1998-05-28 | Bayer Ag | Neue substituierte Pyrazolderivate |
| PL354514A1 (en) | 1999-09-14 | 2004-01-26 | Aventis Pharmaceuticals Inc. | Benzisoxazolyl-, pyridoisoxazolyl- and benzthienyl-phenoxy derivatives useful as d4 |
| AU2002214505A1 (en) | 2000-11-09 | 2002-05-21 | Biovitrum Ab | New use of 4, 5, 6, 7-tetrahydroimidazo-(4,5-c)pyridine derivatives |
| US6982286B2 (en) | 2001-07-12 | 2006-01-03 | Biotie Therapies Corp. | Carbocyclic hydrazino inhibitors of copper-containing amine oxidases |
| WO2003029209A2 (en) | 2001-10-02 | 2003-04-10 | Smithkline Beecham Corporation | Chemical compounds |
| US7456169B2 (en) | 2003-02-27 | 2008-11-25 | Abbott Laboratories Inc. | Heterocyclic kinase inhibitors |
| WO2005014530A2 (en) | 2003-08-08 | 2005-02-17 | La Jolla Pharmaceutical Co. | Inhibitors of semicarbazide-sensitive amine oxidase (ssao) and vap-1 mediated adhesion useful for treatment of diseases |
| ES2319539T3 (es) | 2003-09-17 | 2009-05-08 | Janssen Pharmaceutica Nv | Compuestos heterociclicos condensados como moduladores del receptor de serotonina. |
| JP2007520559A (ja) | 2004-02-03 | 2007-07-26 | アボット・ラボラトリーズ | 治療薬としてのアミノベンゾオキサゾール類 |
| TW200538453A (en) | 2004-04-26 | 2005-12-01 | Bristol Myers Squibb Co | Bicyclic heterocycles as kinase inhibitors |
| WO2006114180A1 (de) | 2005-04-25 | 2006-11-02 | Merck Patent Gmbh | Neuartige aza-heterozyklen als kinase-inhibitoren |
| PT1906965E (pt) | 2005-06-22 | 2015-09-03 | Chemocentryx Inc | Compostos de azaindazol e métodos de utilização |
| US20070293548A1 (en) | 2006-03-31 | 2007-12-20 | Wang Eric Y | Inhibitors of semicarbazide-sensitive amine oxidase (SSAO) and VAP-1 mediated adhesion useful for treatment and prevention of diseases |
| BRPI0710527B8 (pt) | 2006-04-04 | 2021-05-25 | Fibrogen Inc | compostos de pirrolo- e tiazolo-piridina e composição farmacêutica que os compreende |
| GB0610242D0 (en) | 2006-05-23 | 2006-07-05 | Novartis Ag | Organic compounds |
| WO2008088744A1 (en) | 2007-01-17 | 2008-07-24 | Merck & Co., Inc. | Decahydroquinoline analogs as cb2 receptor modulators |
| EP2152716A1 (en) | 2007-05-02 | 2010-02-17 | Novartis Ag | Heterocyclic compounds and their use as pesticides |
| GB0725103D0 (en) | 2007-12-21 | 2008-01-30 | Glaxo Group Ltd | Novel compounds |
| CA2712701A1 (en) | 2008-01-31 | 2009-08-06 | Henning Steinhagen | Cyclic azaindole-3-carboxamides, their preparation and their use as pharmaceuticals |
| WO2009108551A2 (en) * | 2008-02-25 | 2009-09-03 | H. Lundbeck A/S | Heteroaryl amide analogues |
| US8633318B2 (en) | 2008-09-16 | 2014-01-21 | Proximagen Ltd | Compounds for treatment or prevention of inflammation, an inflammatory disease, or an immune or an autoimmune disorder |
| DK2334672T3 (da) | 2008-09-16 | 2013-12-02 | Proximagen Ltd | 4,5,6,7-tetrahydroimidazo[4,5-c]pyridinforbindelser som inhibitorer af SSAO |
| EP2376490B1 (en) | 2008-12-04 | 2013-01-23 | Proximagen Limited | Imidazopyridine compounds |
| JP2012211085A (ja) | 2009-08-12 | 2012-11-01 | Kyowa Hakko Kirin Co Ltd | ヘッジホッグシグナル阻害剤 |
| GB201004311D0 (en) * | 2010-03-15 | 2010-04-28 | Proximagen Ltd | New enzyme inhibitor compounds |
| GB201115853D0 (en) | 2011-09-14 | 2011-10-26 | Proximagen Ltd | New enzyme inhibitor compounds |
-
2011
- 2011-09-14 IN IN1883DEN2014 patent/IN2014DN01883A/en unknown
- 2011-09-14 JP JP2014530103A patent/JP5796130B2/ja not_active Expired - Fee Related
- 2011-09-14 CA CA2847193A patent/CA2847193A1/en not_active Abandoned
- 2011-09-14 EA EA201490451A patent/EA201490451A1/ru unknown
- 2011-09-14 CN CN201180073402.9A patent/CN103889983B/zh not_active Expired - Fee Related
- 2011-09-14 US US14/344,417 patent/US9150574B2/en not_active Expired - Fee Related
- 2011-09-14 SG SG11201400277VA patent/SG11201400277VA/en unknown
- 2011-09-14 BR BR112014005793A patent/BR112014005793A2/pt not_active IP Right Cessation
- 2011-09-14 WO PCT/EP2011/065967 patent/WO2013037411A1/en not_active Ceased
- 2011-09-14 AU AU2011376717A patent/AU2011376717A1/en not_active Abandoned
- 2011-09-14 EP EP11761040.2A patent/EP2755974A1/en not_active Withdrawn
-
2014
- 2014-03-06 IL IL231353A patent/IL231353A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| BR112014005793A2 (pt) | 2017-03-28 |
| US20140357623A1 (en) | 2014-12-04 |
| IL231353A0 (en) | 2014-04-30 |
| WO2013037411A1 (en) | 2013-03-21 |
| JP5796130B2 (ja) | 2015-10-21 |
| CN103889983A (zh) | 2014-06-25 |
| CA2847193A1 (en) | 2013-03-21 |
| IN2014DN01883A (https=) | 2015-05-15 |
| US9150574B2 (en) | 2015-10-06 |
| JP2015502913A (ja) | 2015-01-29 |
| AU2011376717A1 (en) | 2014-03-20 |
| CN103889983B (zh) | 2015-12-09 |
| EP2755974A1 (en) | 2014-07-23 |
| SG11201400277VA (en) | 2014-05-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA201490451A1 (ru) | Новые соединения - ингибиторы ферментов | |
| HRP20190398T1 (hr) | Čvrsti oblik (s)-3-(4-((4-morfolinometil)benzil)oksi)-1-oksoizoindolin-2-il)piperidin-2,6-dion hidroklorida | |
| CY1115376T1 (el) | Βελτιωμενη μεθοδος | |
| ATE486601T1 (de) | Verwendung von 3- (4-amino-1-oxo-1,3-dihydro- isoindol-2-yl)-piperidin--2,6-dion zur behandlung von mantelzelllymphomen | |
| WO2014028445A3 (en) | Cereblon isoforms and their use as biomarkers for therapeutic treatment | |
| IL259694B (en) | Production method for 1-(4-(4-(4,3-dichloro-2-fluorophenylamino)-7-methoxyquinazolin-6-yl-oxy)piperidine-1-yl)-prop-2-en-1-one hydrochloride and intermediates used for this | |
| ME02648B (me) | Jedinjenje pirazin karboksamida | |
| NZ594765A (en) | Anthelmintic agents and their use | |
| RU2010138577A (ru) | ИНГИБИТОРЫ РЕЦЕПТОРА ХЕМОКИНА CxCR3 | |
| HRP20110640T1 (hr) | Derivati cikličkih amida i njihova proizvodnja te njihova uporaba kao antitromboznih sredstava | |
| NZ620635A (en) | Compounds for binding to the platelet specific glycoprotein iib/iiia and their use for imaging of thrombi | |
| NZ630488A (en) | Piperidine derivatives for gpr119 agonist | |
| IL237013B (en) | Methods of treating cancer using 3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione | |
| AR079198A1 (es) | Sales de 4-(2-((5-metil-1-(2-naftalenil) -1h pirazol -3- il)oxi) etil) morfolina | |
| NO20091945L (no) | Myke kapsler omfattende palonosetronhydroklorid med forbedret stabilitet og biotilgjengelighet | |
| NZ592062A (en) | Akt and p70 s6 kinase inhibitors and their use in the treatment of glioblastoma multiforme | |
| AR070936A1 (es) | 1,2,4 -triazoles trisustituidos | |
| SMT201200063B (it) | Composti 4-[2-(-fluorofenossimetil)fenil]piperidinici | |
| DK2167085T3 (da) | 4- [2- (4-methylphenylsulfanyl) phenyl]piperidin til behandling af irritabel tarmsyndrom (ibs) | |
| ATE391716T1 (de) | Monohydrochloridsalz von 1-(3-(3-(4- chlorophenyl)propoxy)propyl)-piperidin | |
| EP4387609A4 (en) | ARYLSULFONYL (HYDROXY)PIPERIDINES AS CCR6 INHIBITORS | |
| UY34856A (es) | Formas de presentación farmacéuticas que contienen 5-cloro-n-({(5s)-2-oxo-3-[4-(3-oxo-4- morfolinil)-fenil]-1,3-oxazolidin-5-il}-metil)-2-tiofencarboxamida | |
| ATE462701T1 (de) | Verfahren zur herstellung von 4-(phenoxy-5-methyl-pyrimidin-4-yloxy)piperidin 1-carboxylsäure- derivaten und damit zusammenhängenden verbindungen | |
| NO20063921L (no) | Nye piperidiner som kjemokinmodulatorer (CCR) | |
| IL240197B (en) | Method for preparing 1-(4-(4-(3,4-dichloro-2-fluorophenylamino)-7-methoxyquinazolin-6-yloxy)piperidin-1-yl)prop-2-en-1-one |